<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775381</url>
  </required_header>
  <id_info>
    <org_study_id>CHRD 2115</org_study_id>
    <secondary_id>2018-000526-64</secondary_id>
    <nct_id>NCT04775381</nct_id>
  </id_info>
  <brief_title>Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation</brief_title>
  <acronym>CAVITHY</acronym>
  <official_title>Study of Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier René Dubos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier René Dubos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study evalue the inflence of pre operative vit D3 administration on post&#xD;
      operative hypocalcemia in patients undergoing Total thyroidectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroidectomy is a frequent procedure. This surgery is well known but not devoid of risks.&#xD;
      The most common postoperative complication is transitory hypocalcemia. Some studies have&#xD;
      reported that preoperative vitamin D deficiency (VDD) is a risk factor for hypocalcemia after&#xD;
      total thyroidectomy (TT) in patients with non toxic multinodular goiter or graves's disease.&#xD;
      Although the association between VVD and postoperative hypocalcemia in thyroid cancer&#xD;
      patients undergoing TT plus central compartment neck dissection (CCND) remains unclear. This&#xD;
      prospective study evalue the inflence of pre operative vit D3 administration on post&#xD;
      operative hypocalcemia in patients undergoing TT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the effect of pre-operative cholecalciferol supplementation on the occurrence of post-operative hypocalcemia after total thyroidectomy</measure>
    <time_frame>At Day 15 after surgery</time_frame>
    <description>Measure of the occurrence of serum and / or clinical hypocalcemia.&#xD;
Serum hypocalcemia is defined by a level of calcemia, corrected for albuminemia, of less than 2.00 mmol / L.&#xD;
Clinical hypocalcemia is defined by the appearance of one of the following signs: sign of Chvostek, sign of Trousseau, paresthesias of the extremities and perioral between surgery and day 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of clinical course in both Arm</measure>
    <time_frame>At 3 month</time_frame>
    <description>Clinical course will be measured, for several items, and compared between both groups to see if a significant difference is observed.&#xD;
Items, considered for comparison, are listed below :&#xD;
Initial hospital stay (number of days),&#xD;
number of readmission,&#xD;
adverse event (number)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of severity of hypocalcemia in both arm</measure>
    <time_frame>At Day 1, Day 2 and Day 15</time_frame>
    <description>The severity of hypocalcemia will be measured in both arm, to see if a significant difference is observed, with items listed below :&#xD;
Calcemia, corrected for albuminemia, of less than 1.90 mmol / L&#xD;
the use of calcium gluconate IV in the first 15 post-operative days)&#xD;
duration of hypocalcemia's symptoms in the first 15 days postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the effect of supplementation on vitamin D deficiency in both arm</measure>
    <time_frame>At Day 0</time_frame>
    <description>Comparison between measured initial value of 25OHD at the inclusion visit to the measured value of 25OHD on the day of the operation in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of parathyroid activity in both arm</measure>
    <time_frame>At Day 0 (= Surgery), at Hour 4 post-surgery, Day 2 and Day 15</time_frame>
    <description>Parathyroid activity will be evaluated in both group by measuring parathormone (PTH).&#xD;
Hypoparathyroidism being defined by PTH &lt; 15 ng / L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the prevalence of definitive hypocalcemia</measure>
    <time_frame>At Day 15</time_frame>
    <description>Collect of the definitive hypocalcemia's numbers in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the effect of vitamin D supplementation on the occurrence of hypocalcemia in risk groups: hyperthyroidism, cancer, dissection associated with thyroidectomy</measure>
    <time_frame>At Day 15</time_frame>
    <description>Collect of the number of adverse events and serum calcium levels for each participant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypocalcemia</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During preoperative visit (Month -2) patients will receive a cholecalciferol supplementation added to a fruit juice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fruit juice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>During preoperative visit (Month -2) patients will receive only fruit juice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Patients will receive a cholecalciferol supplementation added to a fruit juice.</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥ 18 years old&#xD;
&#xD;
          -  Patient shall be operated on for a total thyroidectomy in one time for any indication&#xD;
&#xD;
          -  Written informed consent (IC) obtained&#xD;
&#xD;
          -  Patients with affiliation to the social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Medical history of : Thyroid or parathyroid surgery Hyperparathyroidism Granulomatosis&#xD;
        flare-up&#xD;
&#xD;
          -  Hypocalcemia, hypercalcemia/ hypercalciuria, or symptom of Hypocalcemia,&#xD;
             hypercalcemia/ hypercalciuria, not due to thyroid pathologies&#xD;
&#xD;
          -  Chronic kidney disease grade ≥4&#xD;
&#xD;
          -  Severe liver failure&#xD;
&#xD;
          -  25OHD supplementation within last 3 months before surgery&#xD;
&#xD;
          -  Malabsorption syndrome&#xD;
&#xD;
          -  Known hypersensitivity to vitamin D&#xD;
&#xD;
          -  Medical history of calcic lithiasis&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Vulnerable populations (guardianship or trusteeship)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Khaled AL TABAA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier René Dubos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maryline Delattre</last_name>
    <phone>0033130754131</phone>
    <email>maryline.delattre@ght-novo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veronique Da Costa</last_name>
    <phone>0033130755069</phone>
    <email>veronique.dacosta@ght-novo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Lariboisière, Paris X</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Vincent BEDARIDA</last_name>
      <phone>01 49 95 69 29</phone>
      <email>vincent.bedarida@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Poissy/Saint-Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr Didier SIMON</last_name>
      <phone>01 39 27 42 69</phone>
      <email>didier.simon@ght-yvelinesnord.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital René Dubos,</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Khaled AL TABAA</last_name>
      <phone>01 30 75 71 51</phone>
      <email>khaled.altabaa@ght-novo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total thyroidectomy</keyword>
  <keyword>hypocalcemia</keyword>
  <keyword>cholecalciferol supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypocalcemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

